Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 6268378, 10 pages
https://doi.org/10.1155/2017/6268378
Research Article

Chinese Herbal Medicine Baoyuan Jiedu Decoction Inhibited Muscle Atrophy of Cancer Cachexia through Atrogin-l and MuRF-1

1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China
2Shandong Food and Drug Administration, Jinan, Shandong 250014, China
3College of Foreign Language, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China

Correspondence should be addressed to XuMing Ji; moc.361@427gnimuxij

Received 25 July 2016; Revised 11 January 2017; Accepted 17 January 2017; Published 14 February 2017

Academic Editor: José L. Ríos

Copyright © 2017 YaNan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. G. Fox and T. C. Wang, “Inflammation, atrophy, and gastric cancer,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 60–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Fearon, F. Strasser, S. D. Anker et al., “Definition and classification of cancer cachexia: an international consensus,” The Lancet Oncology, vol. 12, no. 5, pp. 489–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. von Haehling and S. D. Anker, “Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014,” Journal of Cachexia, Sarcopenia and Muscle, vol. 5, no. 4, pp. 261–263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Palesty and S. J. Dudrick, “What we have learned about cachexia in gastrointestinal cancer,” Digestive Diseases, vol. 21, no. 3, pp. 198–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Kir, J. P. White, S. Kleiner et al., “Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia,” Nature, vol. 513, no. 7516, pp. 100–104, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. K. C. H. Fearon, D. J. Glass, and D. C. Guttridge, “Cancer cachexia: mediators, signaling, and metabolic pathways,” Cell Metabolism, vol. 16, no. 2, pp. 153–166, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. Evans, J. E. Morley, J. Argilés et al., “Cachexia: a new definition,” Clinical Nutrition, vol. 27, no. 6, pp. 793–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Tisdale, “Cachexia in cancer patients,” Nature Reviews Cancer, vol. 2, no. 11, pp. 862–871, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. K. A. S. Silva, J. Dong, Y. Dong et al., “Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia,” The Journal of Biological Chemistry, vol. 290, no. 17, pp. 11177–11187, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Zhou, J. L. Wang, J. Lu et al., “Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival,” Cell, vol. 142, no. 4, pp. 531–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Q. Han, X. Zhou, W. E. Mitch, and A. L. Goldberg, “Myostatin/activin pathway antagonism: molecular basis and therapeutic potential,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 10, pp. 2333–2347, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Cohen, J. J. Brault, S. P. Gygi et al., “During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation,” Journal of Cell Biology, vol. 185, no. 6, pp. 1083–1095, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Lagirand-Cantaloube, K. Cornille, A. Csibi, S. Batonnet-Pinchon, M. P. Leibovitch, and S. A. Leibovitch, “Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo,” PLOS ONE, vol. 4, no. 3, Article ID e4973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Pretto, C. Ghilardi, M. Moschetta et al., “Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle,” Oncotarget, vol. 6, no. 5, pp. 3043–3054, 2015. View at Google Scholar
  15. I. Ronga, F. Gallucci, F. Riccardi, and G. Uomo, “Anorexia-cachexia syndrome in pancreatic cancer: recent advances and new pharmacological approach,” Advances in Medical Sciences, vol. 59, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Mantovani, C. Madeddu, and A. Macciò, “Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome,” Drug Design, Development and Therapy, vol. 7, pp. 645–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C.-F. Huang, S.-S. Lin, P.-H. Liao, S.-C. Young, and C.-C. Yang, “The immunopharmaceutical effects and mechanisms of herb medicine,” Cellular and Molecular Immunology, vol. 5, no. 1, pp. 23–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. L. J. Song, B. Ouyang, and X. M. Ji, “Review on Baoyuan Jiedu decoction intervention on active substances of tumor microenvironment,” Liaoning Journal of Traditional Chinese Medicine, vol. 43, no. 3, pp. 656–658, 2016. View at Google Scholar
  19. M. J. Puppa, S. Gao, A. A. Narsale, and J. A. Carson, “Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia,” FASEB Journal, vol. 28, no. 2, pp. 998–1009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. E. Utech, E. M. Tadros, T. G. Hayes, and J. M. Garcia, “Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers,” Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 4, pp. 245–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. B. McLean, J. S. Moylan, E. M. W. Horrell, and F. H. Andrade, “Proteomic analysis of media from lung cancer cells reveals role of 14-3-3 proteins in cachexia,” Frontiers in Physiology, vol. 6, article 136, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Li, R. Gan, Q. Yang et al., “Influence of formulas based on different principles of traditional Chinese medicine on cachexia muscle atrophy of mice induced by CT26 adenocarcinoma,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 30, no. 5, pp. 1696–1699, 2015. View at Google Scholar
  23. R. Piccirillo, F. Demontis, N. Perrimon, and A. L. Goldberg, “Mechanisms of muscle growth and atrophy in mammals and Drosophila,” Developmental Dynamics, vol. 243, no. 2, pp. 201–215, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Fearon, J. Arends, and V. Baracos, “Understanding the mechanisms and treatment options in cancer cachexia,” Nature Reviews Clinical Oncology, vol. 10, no. 2, pp. 90–99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. S. W. Lee, G. Dai, Z. Hu, X. Wang, J. Du, and W. E. Mitch, “Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase,” Journal of the American Society of Nephrology, vol. 15, no. 6, pp. 1537–1545, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Wollersheim, J. Woehlecke, M. Krebs et al., “Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness,” Intensive Care Medicine, vol. 40, no. 4, pp. 528–538, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Schmidt, M. Kny, X. Zhu et al., “The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy,” Critical Care, vol. 18, no. 5, 2014. View at Publisher · View at Google Scholar